These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 566830)

  • 21. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of dopamine receptor sensitivity by estrogen.
    Gordon JH; Borison RL; Diamond BI
    Biol Psychiatry; 1980 Jun; 15(3):389-96. PubMed ID: 7189674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopaminergic supersensitivity: influence of dopamine agonists and drugs used for the treatment of tardive dyskinesia.
    Christensen AV; Nielsen IM
    Adv Biochem Psychopharmacol; 1980; 24():341-9. PubMed ID: 6105784
    [No Abstract]   [Full Text] [Related]  

  • 25. Radio-frequency analysis of the effect of haloperidol and cyclo (leucyl-glycyl) on apomorphine-induced stereotypy.
    Fields JZ; Gonzalez LP; Meyerson LR; Lieber P; Lee JM; Steece KA; DeLeon-Jones FA; Ritzmann RF
    Pharmacol Biochem Behav; 1986 Dec; 25(6):1279-84. PubMed ID: 3809231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of choline and lecithin in the treatment of tardive dyskinesia.
    Zeisel SH; Gelenberg AJ; Growdon JH; Wurtman RJ
    Adv Biochem Psychopharmacol; 1980; 24():463-70. PubMed ID: 6996444
    [No Abstract]   [Full Text] [Related]  

  • 29. A ketamine-induced rat model of tardive dyskinesia.
    Marco LA; Joshi RS
    Prog Neurobiol; 1992 Jun; 38(6):571-600. PubMed ID: 1350352
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa-induced dopamine receptor hypersensitivity.
    Klawans HL; Goetz C; Nausieda PA; Weiner WJ
    Trans Am Neurol Assoc; 1977; 102():80-3. PubMed ID: 616121
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of cholinergic agonists on apomorphine-induced stereotyped behavior in the rat.
    Sahakian BJ; Growdon JH; Millington WR; Barr JK; Wurtman RJ
    Commun Psychopharmacol; 1978; 2(3):255-62. PubMed ID: 568059
    [No Abstract]   [Full Text] [Related]  

  • 32. Cholinergic influences in tardive dyskinesia.
    Tamminga CA; Smith RC; Ericksen SE; Chang S; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):769-74. PubMed ID: 869054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing tardive dyskinesia.
    Casey DE
    J Clin Psychiatry; 1978 Oct; 39(10):748-53. PubMed ID: 30759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of drug holidays in an animal model of tardive dyskinesia.
    Bannet J; Belmaker RH; Ebstein RP
    Psychopharmacology (Berl); 1980; 69(2):223-4. PubMed ID: 6779315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the potential neuroleptic peptide des-tyrosine-gamma-endorphin and haloperidol on apomorphine-induced behavioural syndromes in rats and mice.
    Nickolson VJ; Berendsen HH
    Life Sci; 1980 Oct; 27(15):1377-85. PubMed ID: 7192353
    [No Abstract]   [Full Text] [Related]  

  • 37. Phenytoin potentiation of neuroleptic-induced dyskinesias.
    Sethi KD; Hitri A; Diamond BI
    Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
    Lublin H; Gerlach J
    Eur J Pharmacol; 1988 Aug; 153(2-3):239-45. PubMed ID: 3263277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
    Ikeda H; Adachi K; Hasegawa M; Sato M; Hirose N; Koshikawa N; Cools AR
    J Neural Transm (Vienna); 1999; 106(11-12):1205-16. PubMed ID: 10651114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive dyskinesia.
    Lancet; 1979 Sep; 2(8140):447-8. PubMed ID: 89504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.